Rejuvo

Rejuvo is an innovative company focusing on the research, development, production, and sales of recombinant botulinum toxin. The company is committed to applying synthetic biology technology in the pharmaceutical field to develop and provide a series of botulinum toxin products with excellent cost-performance, aiming to become one of the leading suppliers in this category. At the technological innovation level, relying on its proprietary patented technology, Rejuvo's first pipeline product "DJ-01 Injection" has entered Phase II clinical trials, showing good safety and efficacy. This product was developed based on a technology platform for designing and constructing genetically engineered strains, significantly reducing prominent biosafety risks associated with traditional botulinum toxin production. It greatly improves product purity and quality while maintaining highly competitive costs, fully leveraging the advantages of the engineered strain design platform and recombinant protein technology. With a core team that integrates multiple disciplines and possesses strong comprehensive capabilities, Rejuvo is rapidly advancing product industrialization and has rich experience in recombinant protein R&D, biopharmaceutical development, high-activity pharmaceutical plant construction, drug manufacturing, and the medical aesthetics market expansion.